Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Infect Dis ; 57(6): 828-35, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23788240

ABSTRACT

BACKGROUND: Chronic pulmonary aspergillosis (CPA) is an infectious disease that progressively destroys lung tissue. To date, no longitudinal data on the efficacy of antifungal treatment on health status in CPA patients exist. METHODS: Using the standardized St George's Respiratory Questionnaire, the health status of 122 patients with was assessed at baseline and quarterly over 12 months. The score range was 0-100, where higher score indicates worse heath status, and a change of ≥4 was deemed the minimal clinically important difference. Lung function, body mass index, Medical Research Council dyspnea scale, disease severity, and demographic data were reported. RESULTS: Mean age of patients was 59 years, and 45% were female. Overall, patients with CPA had substantial health status impairment at baseline. After treatment, 47%-50% gained substantial health improvement with a mean reduction of score of 14 at both 6 and 12 months, whereas 32% deteriorated with a mean rise of score of 11 and 14 after 6 and 12 months of treatment and observation, respectively, and 21% were not much different (stable). Patients gained therapeutic benefit irrespective of their illness severity where >50% of those who had "poor" and "very poor" status at baseline improved with score reduction of ≥4 after 6 months of treatment. Replicating this analysis using a health status category, we found that at least 50% of patients with a "poor/very poor" health status category at baseline improved significantly to "fair" or "good/very good" categories. Side effects burdened health status considerably. In multivariate analysis, dyspnea and disease severity significantly defined health status impairment. CONCLUSIONS: Antifungal therapy improved health status and prevented CPA progression in most patients.


Subject(s)
Antifungal Agents/administration & dosage , Pulmonary Aspergillosis/drug therapy , Aged , Chronic Disease , Drug Administration Schedule , Female , Health Status , Humans , Longitudinal Studies , Male , Middle Aged , Surveys and Questionnaires , Treatment Outcome
2.
AIDS ; 20(2): 171-80, 2006 Jan 09.
Article in English | MEDLINE | ID: mdl-16511409

ABSTRACT

OBJECTIVES: The study tests the hypothesis that monocyte derived dendritic cells from HIV-1 infected individuals are normal and can restore impaired CD4 T-cell antigen specific responses. DESIGN: Monocyte derived dendritic cells were isolated from individuals at three different stages of HIV-1 infection with a wide spectrum of viral load and CD4 T-cell counts, and from healthy volunteers. The cell surface phenotype and allogeneic stimulatory potential of these dendritic cells was documented. CD4 T-cell responses to HIV p24, tetanus toxoid and purified protein derivative were measured using either unfractionated peripheral blood mononuclear cells, or purified dendritic cell/T-cell cultures. RESULTS: Dendritic cells from all three HIV-1 infected groups did not differ from each other or from healthy volunteers in terms of cell surface phenotype or allogeneic stimulatory potential using T cells from healthy volunteers. Dendritic cells from immunosuppressed antiretroviral naive individuals enhanced the autologous recall proliferative responses both to HIV-1 p24, and third party antigens tetanus toxoid and purified protein derivative, both in terms of the proportion of responding individuals, and median proliferation. CONCLUSION: Antigen presentation by dendritic cells partially restores impaired antigen specific CD4 T-cell responses associated with HIV-1 infection. Immunization strategies which target dendritic cells may therefore offer significant advantages in the ability to stimulate HIV-specific protective immune responses.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Dendritic Cells/immunology , HIV Infections/immunology , HIV-1/isolation & purification , Adult , Antigen Presentation/immunology , CD4 Lymphocyte Count , Female , HIV Core Protein p24/immunology , HIV Infections/virology , Humans , Immune Tolerance , Immunity, Cellular , Immunophenotyping , Lymphocyte Activation/immunology , Lymphocyte Culture Test, Mixed , Male , Middle Aged , Tetanus Toxoid/immunology , Tuberculin/immunology , Viral Load
3.
Int J Exp Pathol ; 86(4): 187-204, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16045541

ABSTRACT

Dendritic cells (DC) are potent antigen-presenting cells that are critical in the initiation of immune responses to control and/or eliminate viral infections. Recent studies have investigated the effects of virus infection on the biology of DC. This review summarizes these changes, focusing on both the DC parameters affected and the viral factors involved. In addition, the central role of DC biology in the pathogenesis of several viral families, including herpesviruses, paramyxoviruses and retroviruses, is explored. The field of pathogen recognition by DC is addressed, focusing on its role in protecting the host from viral infection, as well as the ability of viruses to exploit such host receptor ligation and signalling to their replicative advantage. The hypothesis is proposed that virus and host have evolved a symbiotic relationship to ensure both viral transmission and host survival.


Subject(s)
Dendritic Cells/immunology , Virus Diseases/immunology , Cell Survival/immunology , Cytokines/immunology , Dendritic Cells/pathology , Filoviridae Infections/immunology , Filoviridae Infections/pathology , Herpesviridae Infections/immunology , Herpesviridae Infections/pathology , Humans , Immunity, Innate , Interleukin-12/immunology , Lectins, C-Type/immunology , Membrane Glycoproteins/immunology , Paramyxoviridae Infections/immunology , Paramyxoviridae Infections/pathology , Phenotype , Receptors, Cell Surface/immunology , Retroviridae Infections/immunology , Retroviridae Infections/pathology , Symbiosis/immunology , Toll-Like Receptors , Virus Diseases/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...